Cholesterol drug may prevent liver cancer in High-Risk patients
NCT ID NCT05028829
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This study tests whether taking atorvastatin (a widely used cholesterol medication) daily for a year can reduce the risk of developing liver cancer in 60 adults with advanced liver fibrosis or cirrhosis. Participants are randomly assigned to receive either atorvastatin or a placebo, and researchers will measure changes in a blood-based risk score for liver cancer. The goal is to see if this safe, affordable drug can prevent cancer in a high-risk population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.